Resource Logo
AIDS Weekly Plus

Reports on Genetics and HIV/AIDS from University of Cape Town Provide New Insights




 



2013 OCT 21 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Investigators publish new report on Immune System Diseases and Conditions. According to news reporting from Cape Town, South Africa, by NewsRx journalists, research stated, "Efavirenz is primarily metabolized by CYP2B6, with a minor contribution from CYP1A2, CYP2A6, CYP3A4 and CYP3A5. Genetic variability in these genes contributes towards differences in plasma efavirenz concentration, which ultimately leads to either development of adverse drug events or emergence of virus resistance."

The news correspondents obtained a quote from the research from the University of Cape Town, "However, the clinical utility or validity of introducing genotype-assisted dosing is not known. The aim of this study was therefore to evaluate the effects of 14 single-nucleotide polymorphisms (SNPs) in five drug-metabolizing enzyme genes on steady-state plasma efavirenz levels in South African HIV/AIDS patients as well as their clinical validity. HIV/AIDS patients were recruited from Themba Lethu Clinic, at Helen Joseph Hospital, Johannesburg. Blood samples for plasma drug levels and DNA extraction were obtained from each participant. PCR/RFLP and SNaPshot genotyping were used for SNPs in CYP1A2, CYP2A6, CYP2B6, CYP3A4 and CYP3A5 among 464 Bantu-speaking South Africans. Plasma efavirenz concentrations were measured using LC/MS/MS. Genotypes and plasma efavirenz levels were used to calculate predictive values. Multivariate analysis was used to select the minimal set of SNPs with significant clinical validity. Qualitative and quantitative differences in allele frequencies were observed when comparing South Africans with African, Caucasian and Asian populations. CYP2B6 516T and 785G (*6) and CYP2B6 983C (*18) alleles were significantly associated with high plasma efavirenz levels. CYP2B6 A-G-A-C-C and A-T-G-T-C haplotypes (with respect to CYP2B6 136A >G; CYP2B6 516G >T; CYP2B6 785A >G; CYP2B6 983T >C; and CYP2B6 1459C >T) were associated with higher levels of efavirenz, whereas G-G-A-T-C and A-G-A-T-C haplotypes showed significantly lower levels of efavirenz. The CYP2B6*1/*6 genotype was significantly associated with an increased risk of loss to follow-up. The sensitivity, specificity and positive predictive values for the CYP2B6*6/*6 genotype in predicting efavirenz levels above 4 g/ml were 46, 97 and 88%, respectively. However, these values improved to 49, 100 and 100%, respectively, when either the CYP1A2 -163A (*1F) allele or the NR1I3 8784C/C genotype was present."

According to the news reporters, the research concluded: "Screening for CYP2B6 516G >T SNP has a high specificity and positive predictive value for efavirenz levels above 4 g/ml and could be used in deciding on efavirenz dosage among individuals homozygous for this variant, which could lead to better precision medication."

For more information on this research see: High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenetics and Genomics, 2013;23(8):415-27. (Lippincott Williams and Wilkins - www.lww.com; Pharmacogenetics and Genomics - journals.lww.com/jpharmacogenetics/pages/default.aspx)

Our news journalists report that additional information may be obtained by contacting M. Swart, Dept. of Clinical Laboratory Science, Division of Human Genetics, University of Cape Town, Cape Town, South Africa. Additional authors for this research include M. Skelton, Y. Ren, P. Smith, S. Takuva and C. Dandara (see also Immune System Diseases and Conditions).

Keywords for this news article include: Blood, Plasma, Genetics, HIV/AIDS, Cape Town, RNA Viruses, South Africa, Retroviridae, HIV Infections, Vertebrate Viruses, Primate Lentiviruses, Viral Sexually Transmitted Diseases, Immune System Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC



 


Copyright © 2013 -AIDS Weekly Plus, Publisher. All rights reserved to Charles Henderson, Publisher. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633- 4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX:(205) 995-1588 Visit AIDS WEEKLY PLUS.



Information in this article was accurate in October 21, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.